STAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and more

Eli Lilly is allowing patients to apply for early access to retatrutide, an unapproved obesity drug, following a special access request for a 79-year-old patient. The California Supreme Court ruled in favor of Gilead Sciences in a case where patients claimed the company was negligent in delaying a safer HIV medication, overturning a prior appeals court decision.